A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
Study Details
Study Description
Brief Summary
Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/㎡（day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced GC in ph1b/2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in combination with Paclitaxel in the treatment of patients with aGC who have progressed after first line standard chemotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
This is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to compare the efficacy and safety of Fruquintinib combined with Paclitaxel versus Paclitaxel alone in patients with advanced gastric cancer who have progressed after first-line standard chemotherapy. After checking eligibility criteria, subjects will be randomized into Fruquintinib combined with Paclitaxel group (treatment group) or placebo combined with Paclitaxel group (control group) in a ratio of 1:1. Primary Efficacy Endpoint: Overall Survival (OS), Progression free survival (PFS) (According to RECIST Version 1.1). Secondary Efficacy Endpoints: Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DOR), EORTC QLQ-C30 (V3) .Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: fruquintinib+paclitaxel treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle. |
Combination Product: fruquintinib +paclitaxel
treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
Other Names:
|
| Placebo Comparator: placebo+paclitaxel control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle. |
Combination Product: fruquintinib placebo + paclitaxel
control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall survival (OS) [from randomization until death due to any cause, assessed up to 3 year]
every two months follow up after EOT observation period at 30 days after the last medication
- Progression free survival (PFS) [from the date of randomization to the date of the first documented progressive disease or date of death due to any cause, assessed up to 1 year]]
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause.
Secondary Outcome Measures
- Objective response rate (ORR) [from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year]
Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1
- Disease control rate (DCR) [from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year]
Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1
- Safety and tolerance evaluated by incidence, severity and outcomes of AEs [from first dose to 30 days post the last dose]
Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.03
- Duration of response, DOR [: From the first documented PR or CR until the first documented PD or death，assessed up to 2 years]
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1.
- Quality of life ( QOL) [Evaluation before the beginning of each treatment cycle, at the end of treatment, and at the 30 days post the last dose，up to 2 years]
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent
-
Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma
-
Metastatic disease or locally advanced, unresectable disease
-
Disease progression during or within 4 months after the last dose of the first-line therapy (with platinum/fluoropyrimidine )
-
Adequate hepatic, renal, heart, and hematologic functions
-
At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)
-
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure
-
Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1
Exclusion Criteria:
-
Pregnant or lactating women
-
Any factors that influence the usage of oral administration
-
Evidence of CNS metastasis
-
Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure
-
Abuse of alcohol or drugs
-
Less than 4 weeks from the last clinical trial
-
Previous treatment with VEGFR inhibition
-
Disability of serious uncontrolled intercurrence infection
-
Proteinuria ≥ 2+ (1.0g/24hr)
-
Have evidence or a history of bleeding tendency within two months of the enrollment randomization, regardless of seriousness
-
Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.
-
Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG
-
Bone fracture or wounds that was not cured for a long time
-
Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant Therapy
-
The tumor invades a large vessel structure, such as the pulmonary artery, superior vena cava, or inferior vena cava
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hutchison Medi Pharma Invesigational sites | Hefei | Anhui | China | 230000 |
| 2 | Hutchison Medi Pharma Investigational Site | Guangzhou | Guangdong | China | 510030 |
| 3 | Hutchison Medi Pharma Investigational site | Harbin | Heilongjiang | China | 150081 |
| 4 | Huchison Medi Pharma Investigational site | Nanjing | Jiangsu | China | 210000 |
| 5 | Hutchison Medi Pharma Investigational sites | Hangzhou | Zhejiang | China | 310000 |
| 6 | Hutchison Medi Pharma Investigational sites | Beijing | China | 100142 | |
| 7 | Hutchison Medi Pharma Investigational site | Shanghai | China | 200125 |
Sponsors and Collaborators
- Hutchison Medipharma Limited
- Sun Yat-sen University
Investigators
- Principal Investigator: Ruihua Xu, MD, Sun Yat-sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2017-013-00CH1